Shkedy D, Gonen H, Bercovich B, Ciechanover A
Department of Biochemistry, Technion-Israel Institute of Technology, Haifa.
FEBS Lett. 1994 Jul 11;348(2):126-30. doi: 10.1016/0014-5793(94)00582-6.
The wild-type tumor suppressor protein p53 is a short-lived protein that plays important roles in regulation of cell cycle, differentiation, and survival. Mutations that inactivate or alter the tumor suppressor activity of the protein seem to be the most common genetic change in human cancer and are frequently associated with changes in its stability. The ubiquitin system has been implicated in the degradation of p53 both in vivo and in vitro. A mutant cell line that harbors a thermolabile ubiquitin-activating enzyme, E1, fails to degrade p53 at the nonpermissive temperature. Studies in cell-free extracts have shown that covalent attachment of ubiquitin to the protein requires the three conjugating enzymes: E1, a novel species of ubiquitin-carrier protein (ubiquitin-conjugating enzyme; UBC),E2-F1, and an ubiquitin-protein ligase, E3. Recognition of p53 by the ligase is facilitated by formation of a complex between the protein and the human papillomavirus (HPV) oncoprotein E6. Therefore, the ligase has been designated E6-associated protein (E6-AP). However, these in vitro studies have not demonstrated that the conjugates serve as essential intermediates in the proteolytic process. In fact, in many cases, conjugation of ubiquitin to the target protein does not signal its degradation. Thus, it is essential to demonstrate that p53-ubiquitin adducts serve as essential proteolytic intermediates and are recognized and degraded by the 26S protease complex, the proteolytic arm of the ubiquitin pathway. In this study, we demonstrate that conjugates of p53 generated in the presence of purified, E1, E2, E6-AP, E6, ubiquitin and ATP, are specifically recognized by the 26S protease complex and degraded. In contrast, unconjugated p53 remains stable. The ability to reconstitute the system from purified components will enable detailed analysis of the recognition process and the structural motifs involved in targeting the protein for degradation.
野生型肿瘤抑制蛋白p53是一种寿命较短的蛋白,在细胞周期调控、分化和存活中发挥重要作用。使该蛋白的肿瘤抑制活性失活或改变的突变似乎是人类癌症中最常见的基因变化,并且常常与其稳定性的改变相关。泛素系统在体内和体外均与p53的降解有关。一个含有热不稳定泛素激活酶E1的突变细胞系在非允许温度下不能降解p53。无细胞提取物研究表明,泛素与该蛋白的共价连接需要三种缀合酶:E1、一种新型泛素载体蛋白(泛素缀合酶;UBC)E2-F1和一种泛素蛋白连接酶E3。该连接酶对p53的识别通过该蛋白与人乳头瘤病毒(HPV)癌蛋白E6之间形成复合物而得以促进。因此,该连接酶被命名为E6相关蛋白(E6-AP)。然而,这些体外研究尚未证明缀合物在蛋白水解过程中作为必需中间体。事实上,在许多情况下,泛素与靶蛋白的缀合并不表明其会被降解。因此,必须证明p53-泛素加合物作为必需的蛋白水解中间体,并被26S蛋白酶复合物(泛素途径的蛋白水解分支)识别和降解。在本研究中,我们证明在纯化的E1、E2、E6-AP、E6、泛素和ATP存在下生成的p53缀合物被26S蛋白酶复合物特异性识别并降解。相比之下,未缀合的p53保持稳定。从纯化成分重建该系统的能力将有助于对识别过程以及靶向该蛋白进行降解所涉及的结构基序进行详细分析。